Radezolid

Radezolid

Clinical data
Routes of administration	Intravenous infusion, oral
ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name N-{[(5S)-3-(2-fluoro-4′-{[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
CAS Number	869884-78-6
PubChem CID	11224409
ChemSpider	9399462
UNII	53PC6LO35W
ChEMBL	ChEMBL455461
CompTox Dashboard (EPA)	DTXSID301007238
Chemical and physical data
Formula	C22H23FN6O3
Molar mass	438.463 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(c(c2)F)c3ccc(cc3)CNCc4cnn[nH]4

Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Melinta Therapeutics, Inc. for the treatment of bacterial acne. ^[1]

References

1. Stearns, John (August 1, 2016). "Melinta Therapeutics takes aim at deadly drug-resistant bacteria". Hartford Business Journal. Archived from the original on April 22, 2019. Retrieved July 10, 2017.

Further reading

• Zhou J, Bhattacharjee A, Chen S, et al. (December 2008). "Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics". Bioorg. Med. Chem. Lett. 18 (23): 6175–8. doi:10.1016/j.bmcl.2008.10.011. PMID   18947996.
• Skripkin E, McConnell TS, DeVito J, et al. (October 2008). "Rχ-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance". Antimicrob. Agents Chemother. 52 (10): 3550–7. doi:10.1128/AAC.01193-07. PMC   2565890 . PMID   18663023.
• Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J (May 2008). "In vitro activities of the Rχ-01 oxazolidinones against hospital and community pathogens". Antimicrob. Agents Chemother. 52 (5): 1653–62. doi:10.1128/AAC.01383-07. PMC   2346622 . PMID   18316525.
• Hanselmann R, Job G, Johnson G, Lou R, Martynow JG, Reeve MM (2009). "Synthesis of an antibacterial compound containing a 1,4-substituted 1H-1,2,3-triazole- a scaleable [sic] alternative to the "click" reaction"". Organic Process Research & Development. 14: 152–158. doi:10.1021/op900252a.
• Franceschi F, Duffy EM (March 2006). "Structure-based drug design meets the ribosome". Biochem. Pharmacol. 71 (7): 1016–25. doi:10.1016/j.bcp.2005.12.026. PMID   16443192.
• Ohlsen K (November 2009). "Novel antibiotics for the treatment of Staphylococcus aureus". Expert Rev. Clin. Pharmacol. 2 (6): 661–72. doi:10.1586/ecp.09.26. PMID   22112259. S2CID   36016568.